Necrotizing vasculitis triggered by gefitinib: An unusual clinical presentation

Journal of Clinical Oncology

Volumn 29, Issue 7, 2011, Pages

  Ko, Jui Hung ^a   Shih, Yi Chin ^a   Hui, Rosaline Chung Yee ^b   Yang, Chih Hsun ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

GEFITINIB; PREDNISOLONE;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CANCER STAGING; CASE REPORT; CLINICAL ASSESSMENT; CLINICAL FEATURE; DYSPNEA; ERYTHROCYTE; HISTOPATHOLOGIC SKIN REACTION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTE; MALE; NECROTIZING ARTERITIS; NEUTROPHIL; PLEURA EFFUSION; PRIORITY JOURNAL; PURPURIC RASH; SKIN BIOPSY;

ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; CARCINOMA, NON-SMALL-CELL LUNG; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LOWER EXTREMITY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NECROSIS; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PREDNISOLONE; QUINAZOLINES; RISK ASSESSMENT; SKIN DISEASES, VASCULAR; TREATMENT OUTCOME; VASCULITIS;

EID: 79952298209     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2010.31.8352     Document Type: Article

References (7)

1. Lenz HJ: Anti-EGFR mechanism of action: Antitumor effect and underlying cause of adverse events. Oncology (Williston Park) 20:5-13, 2006 (suppl 2)
2. Lee MW, Seo CW, Kim SW, et al: Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor. Acta Derm Venereol 84:23-26, 2004
3. Kurokawa I, Endo K, Hirabayashi M: Purpuric drug eruption possibly due to gefinitib (Iressa). Int J Dermatol 44:167-168, 2005 (Pubitemid 40305542)
4. Agero AL, Dusza SW, Benvenuto-Andrade C, et al: Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657-670, 2006 (Pubitemid 44436627)
5. Fernández-Guarino M, Ryan AM, Pérez-García B, et al: Necrotizing vasculitis due to gefitinib (Iressa). Int J Dermatol 46:890-891, 2007 (Pubitemid 47162803)
6. Segaert S, Van Cutsem E: Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425-1433, 2005 (Pubitemid 41222414)
7. Nagasaka T, Miyamoto J, Ishibashi M, et al: MPO-ANCA- and IgA-positive systemic vasculitis: A possibly overlapping syndrome of microscopic polyangiitis and Henoch-Schoenlein purpura. J Cutan Pathol 36:871-877, 2009